<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751087</url>
  </required_header>
  <id_info>
    <org_study_id>9-500-25.1</org_study_id>
    <secondary_id>SFPRF6-MS</secondary_id>
    <nct_id>NCT01751087</nct_id>
    <nct_alias>NCT01799928</nct_alias>
  </id_info>
  <brief_title>Cervical Preparation Before Dilation and Evacuation</brief_title>
  <official_title>Cervical Preparation Before Dilation and Evacuation in the Second Trimester: A Multicenter Randomized Trial Comparing Osmotic Dilators Alone to Dilators Plus Adjunctive Misoprostol or Adjunctive Mifepristone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Planned Parenthood League of Massachusetts</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Planned Parenthood League of Massachusetts</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare three different ways of opening a woman's
      cervix before her second-trimester surgical abortion.

        -  Osmotic dilators: small rods that, when inserted into the cervix, gently expand to open
           the cervix

        -  Osmotic dilators plus mifepristone, a medicine that is swallowed

        -  Osmotic dilators plus misoprostol, a medicine that is placed between the cheek and gum

      Hypotheses:

        -  adding buccal misoprostol 3 hours preoperatively will significantly improve dilation
           compared to laminaria alone, making procedures faster, easier and safer.

        -  adding oral mifepristone at the time of laminaria placement will confer a similar
           benefit.

        -  the efficacy of adjunctive misoprostol and mifepristone will be influenced by
           gestational age, with women later in gestation having increased efficacy from these
           agents.

        -  significantly more patients who receive adjunctive misoprostol or mifepristone will have
           adequate initial dilation, fewer will require manual dilation or additional cervical
           preparation and there will be fewer complications in these arms, although complication
           rates will be low and we will only be able to detect relatively large differences.

        -  patients will prefer to have the procedure done as quickly as possible with as little
           discomfort as possible, that cervical ripening with adjunctive misoprostol will be
           associated with more cramping than osmotic dilators alone and that mifepristone will be
           well tolerated and may not cause more cramping or other side effects than osmotic
           dilators alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative Time</measure>
    <time_frame>participants were assessed for the duration of the procedure, an average of 6 minutes</time_frame>
    <description>The duration of the D&amp;E procedure was measured with a stopwatch, starting with the first instrument that passes into the uterus and ending when the last instrument is removed from the uterus upon completion of the D&amp;E</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial Cervical Dilation</measure>
    <time_frame>participants were assessed during cervical dilation process, average time of 1 minute</time_frame>
    <description>Measured at the time of procedure (immediately before the start of D&amp;E)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to Complete the D&amp;E on the First Attempt</measure>
    <time_frame>participants were assessed for the duration of the procedure, an average of 6 minutes</time_frame>
    <description>Assessed on day of procedure and following day. If the procedure was unable to be completed as planned and the subject had to leave the procedure room and return for another attempt either at a time later the same day or the next day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Mechanical Dilation</measure>
    <time_frame>participants were assessed for the duration of the procedure, an average of 6 minutes</time_frame>
    <description>Assessed on Day of procedure. Assessed immediately after completion of D&amp;E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Mechanical Dilation</measure>
    <time_frame>participants were assessed for the duration of the procedure, an average of 6 minutes</time_frame>
    <description>Number of participants for whom, if additional mechanical dilation was required, it was difficult or very difficult. Assessed on day of procedure. Assessed after completion of D&amp;E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications From Procedure</measure>
    <time_frame>assessed immediately after completion of D&amp;E and at 1 week and 1 month post-procedure</time_frame>
    <description>Patient having any complication, including hospitalizations transfusions additional unplanned procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chills (Any) After Day 2 Medication Administration</measure>
    <time_frame>assessed immediately after administration of day 2 medication</time_frame>
    <description>chills (any) after Day 2 medication administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Cervical Prep</measure>
    <time_frame>patients' satisfaction with cervical prep was evaluated over course of cervical prep and procedure, up to 3 days</time_frame>
    <description>Patients who were very satisfied or satisfied with cervical preparation. Assessed on Day of procedure. Assessed after completion of D&amp;E procedure and just prior to discharge home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Satisfaction With Cervical Preparation</measure>
    <time_frame>physicians' satisfaction with cervical prep was evaluated over course of procedure, an average of 6 minutes</time_frame>
    <description>Participants for whom the operating physician reported being satisfied or very satisfied with the cervical preparation. Assessed on Day of procedure. Assessed after completion of D&amp;E procedure.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Abortion, Induced</condition>
  <arm_group>
    <arm_group_label>Osmotic dilators + placebo (vit c) + placebo (vit B12)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osmotic dilators + placebo (vit c) + misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osmotic dilators + mifepristone + placebo (vit B12)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>oral mifepristone 200 mg on Day 1.</description>
    <arm_group_label>Osmotic dilators + mifepristone + placebo (vit B12)</arm_group_label>
    <other_name>Mifeprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>buccal misoprostol 400 mcg on Day 2</description>
    <arm_group_label>Osmotic dilators + placebo (vit c) + misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Osmotic dilators</intervention_name>
    <description>osmotic dilators on Day 1</description>
    <arm_group_label>Osmotic dilators + placebo (vit c) + placebo (vit B12)</arm_group_label>
    <arm_group_label>Osmotic dilators + placebo (vit c) + misoprostol</arm_group_label>
    <arm_group_label>Osmotic dilators + mifepristone + placebo (vit B12)</arm_group_label>
    <other_name>laminaria</other_name>
    <other_name>Dilapan-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo for mifepristone, on day 1</description>
    <arm_group_label>Osmotic dilators + placebo (vit c) + placebo (vit B12)</arm_group_label>
    <arm_group_label>Osmotic dilators + placebo (vit c) + misoprostol</arm_group_label>
    <other_name>vitamin C 500 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo for misoprostol, on day 2</description>
    <arm_group_label>Osmotic dilators + placebo (vit c) + placebo (vit B12)</arm_group_label>
    <arm_group_label>Osmotic dilators + mifepristone + placebo (vit B12)</arm_group_label>
    <other_name>vitamin B12 500 mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  Able to give informed consent

          -  Medically eligible for outpatient second trimester pregnancy termination at the
             clinical site

          -  English-speaking or Spanish-speaking at sites with ability to obtain informed consent
             in Spanish

        Exclusion Criteria:

          -  Active bleeding (&gt;1 pad/hour) or hemodynamically unstable at enrollment

          -  Signs of chorioamnionitis or clinical infection at enrollment

          -  Signs of spontaneous labor or cervical insufficiency at enrollment

          -  Spontaneous intrauterine fetal demise

          -  Patient incarcerated

          -  Allergy to mifepristone or misoprostol

          -  Chronic steroid use or adrenal insufficiency

          -  Porphyria

          -  Inflammatory bowel disease requiring treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Planned Parenthood League of Massachusetts</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Planning Associates</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of New York City</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovejoy Surgical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee Women's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>December 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <results_first_submitted>September 2, 2015</results_first_submitted>
  <results_first_submitted_qc>January 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2016</results_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abortion, induced</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: February 2013-February 2014
Number of recruitment sites: 7
Types of location: medical clinic (3), hospital-based (4)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
          <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
        </group>
        <group group_id="P2">
          <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
          <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
        </group>
        <group group_id="P3">
          <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
          <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
          <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
        </group>
        <group group_id="B2">
          <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
          <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
        </group>
        <group group_id="B3">
          <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
          <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.6" spread="5.7"/>
                    <measurement group_id="B2" value="25.9" spread="5.9"/>
                    <measurement group_id="B3" value="25.3" spread="5.8"/>
                    <measurement group_id="B4" value="25.25" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American or black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White or European American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Operative Time</title>
        <description>The duration of the D&amp;E procedure was measured with a stopwatch, starting with the first instrument that passes into the uterus and ending when the last instrument is removed from the uterus upon completion of the D&amp;E</description>
        <time_frame>participants were assessed for the duration of the procedure, an average of 6 minutes</time_frame>
        <population>Arm 1 (dilators-alone): 1 subject excluded [withdrawn/no intervention]. Arm 2 (dilators + misoprostol): 2 excluded: [one expelled, no D&amp;E, one D&amp;E not completed on first attempt &amp; data missing]. Arm 3 (dilators + mifepristone): 2 excluded (1 withdrawn/no intervention, 1 D&amp;E not completed on first attempt &amp; data missing].</population>
        <group_list>
          <group group_id="O1">
            <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
          </group>
          <group group_id="O3">
            <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Operative Time</title>
          <description>The duration of the D&amp;E procedure was measured with a stopwatch, starting with the first instrument that passes into the uterus and ending when the last instrument is removed from the uterus upon completion of the D&amp;E</description>
          <population>Arm 1 (dilators-alone): 1 subject excluded [withdrawn/no intervention]. Arm 2 (dilators + misoprostol): 2 excluded: [one expelled, no D&amp;E, one D&amp;E not completed on first attempt &amp; data missing]. Arm 3 (dilators + mifepristone): 2 excluded (1 withdrawn/no intervention, 1 D&amp;E not completed on first attempt &amp; data missing].</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.27" spread="3.5"/>
                    <measurement group_id="O2" value="6.28" spread="4.6"/>
                    <measurement group_id="O3" value="5.53" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Cervical Dilation</title>
        <description>Measured at the time of procedure (immediately before the start of D&amp;E)</description>
        <time_frame>participants were assessed during cervical dilation process, average time of 1 minute</time_frame>
        <population>Arm 1: 1 subject excluded [withdrawn/no intervention]. Arm 2: 2 excluded: [one expelled, no D&amp;E, one D&amp;E not completed on first attempt &amp; data missing]. Arm 3: 2 excluded (1 withdrawn/no intervention, 1 D&amp;E not completed on first attempt &amp; data missing]. Additionally missing data for one more subject in Arm 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
          </group>
          <group group_id="O3">
            <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Cervical Dilation</title>
          <description>Measured at the time of procedure (immediately before the start of D&amp;E)</description>
          <population>Arm 1: 1 subject excluded [withdrawn/no intervention]. Arm 2: 2 excluded: [one expelled, no D&amp;E, one D&amp;E not completed on first attempt &amp; data missing]. Arm 3: 2 excluded (1 withdrawn/no intervention, 1 D&amp;E not completed on first attempt &amp; data missing]. Additionally missing data for one more subject in Arm 2.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.5"/>
                    <measurement group_id="O2" value="2.5" spread="0.9"/>
                    <measurement group_id="O3" value="2.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ability to Complete the D&amp;E on the First Attempt</title>
        <description>Assessed on day of procedure and following day. If the procedure was unable to be completed as planned and the subject had to leave the procedure room and return for another attempt either at a time later the same day or the next day.</description>
        <time_frame>participants were assessed for the duration of the procedure, an average of 6 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
          </group>
          <group group_id="O3">
            <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Ability to Complete the D&amp;E on the First Attempt</title>
          <description>Assessed on day of procedure and following day. If the procedure was unable to be completed as planned and the subject had to leave the procedure room and return for another attempt either at a time later the same day or the next day.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Mechanical Dilation</title>
        <description>Assessed on Day of procedure. Assessed immediately after completion of D&amp;E</description>
        <time_frame>participants were assessed for the duration of the procedure, an average of 6 minutes</time_frame>
        <population>Arm 1: one subject withdrawn/no intervention. Arm 2: one subject expelled, no D&amp;E. Arm 3: one subject withdrawn/no intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
          </group>
          <group group_id="O3">
            <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Mechanical Dilation</title>
          <description>Assessed on Day of procedure. Assessed immediately after completion of D&amp;E</description>
          <population>Arm 1: one subject withdrawn/no intervention. Arm 2: one subject expelled, no D&amp;E. Arm 3: one subject withdrawn/no intervention</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="17.8" upper_limit="35.3"/>
                    <measurement group_id="O2" value="9" lower_limit="3.4" upper_limit="14.8"/>
                    <measurement group_id="O3" value="16" lower_limit="8.9" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ease of Mechanical Dilation</title>
        <description>Number of participants for whom, if additional mechanical dilation was required, it was difficult or very difficult. Assessed on day of procedure. Assessed after completion of D&amp;E</description>
        <time_frame>participants were assessed for the duration of the procedure, an average of 6 minutes</time_frame>
        <population>Number of participants in each arm who required additional mechanical dilation</population>
        <group_list>
          <group group_id="O1">
            <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
          </group>
          <group group_id="O3">
            <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Ease of Mechanical Dilation</title>
          <description>Number of participants for whom, if additional mechanical dilation was required, it was difficult or very difficult. Assessed on day of procedure. Assessed after completion of D&amp;E</description>
          <population>Number of participants in each arm who required additional mechanical dilation</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications From Procedure</title>
        <description>Patient having any complication, including hospitalizations transfusions additional unplanned procedures</description>
        <time_frame>assessed immediately after completion of D&amp;E and at 1 week and 1 month post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
          </group>
          <group group_id="O3">
            <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Complications From Procedure</title>
          <description>Patient having any complication, including hospitalizations transfusions additional unplanned procedures</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chills (Any) After Day 2 Medication Administration</title>
        <description>chills (any) after Day 2 medication administration</description>
        <time_frame>assessed immediately after administration of day 2 medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
          </group>
          <group group_id="O3">
            <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Chills (Any) After Day 2 Medication Administration</title>
          <description>chills (any) after Day 2 medication administration</description>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="5.7" upper_limit="18.6"/>
                    <measurement group_id="O2" value="39" lower_limit="29.4" upper_limit="48.6"/>
                    <measurement group_id="O3" value="18" lower_limit="10.6" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Cervical Prep</title>
        <description>Patients who were very satisfied or satisfied with cervical preparation. Assessed on Day of procedure. Assessed after completion of D&amp;E procedure and just prior to discharge home.</description>
        <time_frame>patients' satisfaction with cervical prep was evaluated over course of cervical prep and procedure, up to 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
          </group>
          <group group_id="O3">
            <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Cervical Prep</title>
          <description>Patients who were very satisfied or satisfied with cervical preparation. Assessed on Day of procedure. Assessed after completion of D&amp;E procedure and just prior to discharge home.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Satisfaction With Cervical Preparation</title>
        <description>Participants for whom the operating physician reported being satisfied or very satisfied with the cervical preparation. Assessed on Day of procedure. Assessed after completion of D&amp;E procedure.</description>
        <time_frame>physicians' satisfaction with cervical prep was evaluated over course of procedure, an average of 6 minutes</time_frame>
        <population>Data on whether the physician was satisfied with the cervical preparation is available for all participants except:
Arm 1: 1 participant withdrawn with no intervention; Arm 2: 1 participant who didn't have a D&amp;E (expelled), Arm 3: 1 participant withdrawn with no intervention and one with missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
          <group group_id="O2">
            <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
            <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
          </group>
          <group group_id="O3">
            <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
            <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Satisfaction With Cervical Preparation</title>
          <description>Participants for whom the operating physician reported being satisfied or very satisfied with the cervical preparation. Assessed on Day of procedure. Assessed after completion of D&amp;E procedure.</description>
          <population>Data on whether the physician was satisfied with the cervical preparation is available for all participants except:
Arm 1: 1 participant withdrawn with no intervention; Arm 2: 1 participant who didn't have a D&amp;E (expelled), Arm 3: 1 participant withdrawn with no intervention and one with missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="62.9" upper_limit="80.6"/>
                    <measurement group_id="O2" value="78" lower_limit="70.7" upper_limit="86.8"/>
                    <measurement group_id="O3" value="85" lower_limit="80.0" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month post-procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Osmotic Dilators + Placebo (Vit c) + Placebo (Vit B12)</title>
          <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1
placebo: placebo for misoprostol, on day 2</description>
        </group>
        <group group_id="E2">
          <title>Osmotic Dilators + Placebo (Vit c) + Misoprostol</title>
          <description>Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
misoprostol: buccal misoprostol 400 mcg on Day 2
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for mifepristone, on day 1</description>
        </group>
        <group group_id="E3">
          <title>Osmotic Dilators + Mifepristone + Placebo (Vit B12)</title>
          <description>Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Mifepristone: oral mifepristone 200 mg on Day 1.
Osmotic dilators: osmotic dilators on Day 1
placebo: placebo for misoprostol, on day 2</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hospitalization for bleeding + Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>uterine re-aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Intrauterine tamponade or cervical stay sutures</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>cervical laceration requiring sutures</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include inadequate sample size to measure complications as a primary outcome and reliance on outcomes that measure efficacy of the cervical preparation rather than its direct effect on overall safety.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Planned Parenthood League of Massachusetts, Inc.</organization>
      <phone>617.616.1600</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

